Novartis to Buy Takeda Eye Drug Assets in $5.3 Billion Deal
A logo sits outside the headquarters of Novartis AG in Basel, Switzerland. (Photographer: Gianluca Colla/Bloomberg)

Novartis to Buy Takeda Eye Drug Assets in $5.3 Billion Deal

(Bloomberg) -- Novartis AG agreed to buy eye-disease medicines from Takeda Pharmaceutical Co. for as much as $5.3 billion as the Japanese company moves to shed debt after its acquisition of Shire P...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.